According to Branislav Bystricky, Faculty Hospital TN-Fakultna nemocnica Trencin, Slovakia and Associate Editor of the Daily Reporter practice changing results for women with ovarian cancer will be presented at ESMO 2019 Congress, held in Barcelona, Spain, from 27 September to 1 October. Findings will likely respond to a key question in oncology around the potential expanded role of these agents beyond the treatment of BRCA mutation in ovarian cancer.
Will PARP inhibitors expand their role beyond BRCA mutations?
